Erratum

In the Drug Evaluation entitled “Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia” by Claude C Schulman, published in the June 2008 issue of Expert Opinion on Drug Metabolism & Toxicology (Expert Opin. Drug Metab. Toxicol. (2008) 4(6):771-782), it has been brought to our attention that Figure 3 on page 777 should have been published as follows:

The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.

Figure 3. Percentage of patients with adverse events and discontinued due to adverse events in direct comparative studies with alfuzosin versus tamsulosin MR 0.4 mg o.d. and terazosin versus tamsulosin MR 0.4 mg once daily. Buzelin et al. [41], n = 256 drug-related adverse events, CV adverse events: e.g., dizziness, headache, palpitation/tachycardia, symptomatic postural hypotension and syncope; Nordling et al. [42], n = 466 treatment-emergent adverse events; Narayan et al. [43], n = 1983 treatment-emergent adverse events reported by ≥ 5% of patients; no data were reported for syncope or postural hypotension.

Notes